Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:10/3/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Oct. 3 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S. pivotal phase III MAESTRO-03 trial of dirucotide (MBP8298) in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the third of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

About MAESTRO-03

----------------

The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study that has completed recruitment of approximately 510 patients at 68 clinical sites who will be administered either dirucotide (MBP8298) or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Revolutionary Science, the manufacturer of the IncuCount ... they have expanded their colony counter product line to ... and ImpressCount. These affordable colony counters that range ... microbiology and pharmaceutical manufacturing. , The previously released IncuCount ... white enclosure with jet black accents represent the updated ...
(Date:5/21/2013)... Inflamax scientists worked closely with internationally ... the study, which will provide critical insight into ... in the study of allergy treatments, the Environmental ... models. Although both the models are well recognized ... direct comparison between the allergic responses evoked by ...
(Date:5/21/2013)... Boston, MA (PRWEB) May 21, 2013 Possible ... parents. And so, according to a report from eagletribune.com posted ... for mold. In case the result is positive, My Cleaning ... without using harmful chemical ingredients. , It was said in ... re-infestation in the campus sparked after a first-grade ...
(Date:5/21/2013)... WOBURN, MA (PRWEB) May 21, 2013 ... for rapid bacterial strain typing, announced today that it ... 250 pathogenic E. coli strains obtained from the Centers ... Genome Sequence Scanning™ (GSS™) technology. The findings are detailed ... Meeting of the American Society for Microbiology in Denver ...
Breaking Biology Technology:Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 3New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 3
... major goal on the path toward making useful superconducting ... at the nanoscale the realm of billionths of ... devices such as superconductive transistors and eventually in ultrafast, ... of Nature, scientists at the U.S. Department ...
... Corporate Restructuring to Focus on Strategic Alliances ... ... 8 Nventa Biopharmaceuticals,Corporation (TSX: NVN), a company developing innovative therapeutics ... on,its ongoing development programs. The company also announced that it will,initiate ...
... CALGARY, Oct. 8 /PRNewswire-FirstCall/ - Oncolytics Biotech ... has,successfully completed initial scale up of its ... The scale up of primary production and ... Research Council Biotechnology,Research Institute (NRC-BRI) located in ...
Cached Biology Technology:Scientists engineer superconducting thin films 2Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR 2Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR 3Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR 4Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR 5Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR 6Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR 7Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR 8Oncolytics Biotech Inc. Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R) to Commercial Scale 2
(Date:5/19/2013)... white men and women of European descent inherit common ... toe deformities, including hammer or claw toe. Findings from ... of foot disorders in humansappear in Arthritis Care ... behalf of the American College of Rheumatology (ACR). ... of older adults have foot disorders which may limit ...
(Date:5/19/2013)... at the University of California, Davis have engineered a ... for light. They report their findings today at ... Microbiology. , "In this work, we used synthetic biology ... carbon dioxide and light energy for growth) cyanobacterial metabolism ... Jordan McEwen, the lead researcher on the study. ...
(Date:5/18/2013)... (May 18, 2013) Research presented today at Digestive ... research, with findings about the impact of coffee on ... , While coffee consumption recently has been associated with ... even a few more cups of java each month ... liver disease. Researchers at the Mayo Clinic, Rochester, MN, ...
Breaking Biology News(10 mins):Blame your parents for bunion woes 2Coffee consumption associated with reduced risk of autoimmune liver disease 2
... higher levels of iron can have an important impact ... in the Journal of Nutrition. The research, conducted by ... a major step forward in the battle against iron ... intractable public health problems affecting nearly 2 billion people. ...
... areas of south and central America such as the Amazon ... with only around 65 species in Britain. UCL scientists have ... wildlife to climate change, in a paper published on 7th ... (Biological Sciences). , Instead, scientists believe that biology played ...
... devised a strategy to treat tumors by selectively targeting ... published in the open access journal PLoS Medicine, has ... is the most aggressive form of brain tumour, growing ... patients within a year of diagnosis. , Working ...
Cached Biology News:Study finds that nutritionally enhanced rice reduces iron deficiency 2Study finds that nutritionally enhanced rice reduces iron deficiency 3Why the Amazon rainforest is so rich in species 2Why the Amazon rainforest is so rich in species 3Preclinical study of a new brain tumor therapy 2
... Detection Assay is an anchorage-independent growth assay ... most stringent assay for detecting malignant transformation ... (pre-treated with carcinogens or carcinogen inhibitors) are ... medium for 21-28 days. Following this ...
... EZ DNA Methylation Kit uses a simplified ... DNA methylation analysis. The kit is based ... place between cytosine and sodium bisulfite where ... DNA Methylation Kits innovative in-column desulphonation reaction ...
... standard is a lyophilized mixture of ... molecular weights range from 152 to ... use with the Aminex HPX-87C column ... column testing or semiquantitative determination. Supplied ...
... from KUBTEC is a dual capability system with ... representation of the specimen under test. While the ... images, the micro focus source also allows the ... standard 2D images. The 50 mm x 50 ...
Biology Products: